Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
19.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 08, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
May 05, 2025
Phase 2 study fully enrolled; data expected in 2H 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
April 28, 2025
Via
Benzinga
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
February 28, 2025
Via
Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
January 29, 2025
Via
Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
December 20, 2024
Via
Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
April 28, 2025
Via
Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
March 20, 2025
Via
Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
March 20, 2025
Via
Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
March 04, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 03, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
November 20, 2024
Via
Benzinga
Analyst Expectations For Celldex Therapeutics's Future
October 28, 2024
Via
Benzinga
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 27, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 18, 2025
Via
Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
January 08, 2025
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Via
Benzinga
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
September 25, 2024
Via
Benzinga
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
September 09, 2024
Via
Benzinga
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 19, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 20, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
7 Analysts Have This To Say About Celldex Therapeutics
August 12, 2024
Via
Benzinga
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
September 27, 2024
Via
Benzinga
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
